Biotech Co. Must Face Investor Suit Over Misleading Claims

By Sydney Price · June 26, 2025, 7:47 PM EDT

Biotech company CytoDyn and its former executives and directors cannot escape a suit accusing them of misleading shareholders about the likelihood that the U.S. Food and Drug Administration would approve its...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login